JAN (NYSE:JAN) Price Target Raised to $33.00 at Scotiabank

JAN (NYSE:JAN) had its target price hoisted by research analysts at Scotiabank from $31.00 to $33.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has a “sector outperform” rating on the stock. Scotiabank’s target price would suggest a potential upside of 8.43% from the company’s previous close.

Several other analysts also recently issued reports on the stock. UBS Group set a $29.00 price target on shares of JAN in a report on Thursday, June 18th. Wall Street Zen upgraded JAN from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Zacks Research lowered shares of JAN from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. lifted their price target on shares of JAN from $30.00 to $34.00 and gave the stock an “overweight” rating in a report on Tuesday, August 18th. Finally, Compass Point began coverage on JAN in a research note on Wednesday. They set a “neutral” rating and a $37.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, JAN has a consensus rating of “Moderate Buy” and an average price target of $32.44.

JAN Stock Down 0.4%

Shares of JAN traded down $0.12 during trading hours on Thursday, reaching $30.43. The company had a trading volume of 333,708 shares, compared to its average volume of 1,410,172. JAN has a 12-month low of $22.76 and a 12-month high of $32.83. The firm has a 50 day moving average of $30.48.

JAN (NYSE:JAN) last posted its earnings results on Tuesday, August 4th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.18). The business had revenue of $216.46 million during the quarter, compared to the consensus estimate of $203.32 million. The company’s quarterly revenue was up 45.4% compared to the same quarter last year. JAN has set its FY 2026 guidance at 0.950-0.980 EPS. On average, research analysts anticipate that JAN will post 0.97 EPS for the current year.

Institutional Trading of JAN

A number of institutional investors have recently modified their holdings of the company. Greenland Capital Management LP acquired a new stake in JAN during the 2nd quarter worth approximately $575,000. Readystate Asset Management LP purchased a new stake in JAN during the 2nd quarter worth $1,724,000. WINTON GROUP Ltd acquired a new stake in JAN in the 2nd quarter valued at $2,985,000. Wellington Management Group LLP purchased a new position in JAN in the second quarter valued at about $8,739,000. Finally, Engineers Gate Manager LP acquired a new position in shares of JAN during the second quarter worth about $15,274,000. Hedge funds and other institutional investors own 6.27% of the company’s stock.

More JAN News

Here are the key news stories impacting JAN this week:

• Positive Sentiment: Jefferies initiated coverage with a “buy” rating and a $36 price target, implying roughly 18% upside from the referenced $30.44 share price. The call supports the view that JAN’s growth outlook and valuation may be attractive.
• Positive Sentiment: Compass Point began coverage with a “neutral” rating and a $37 price target, implying approximately 22% upside. However, the neutral rating indicates the firm is not yet convinced that the potential upside warrants a stronger bullish stance.
• Neutral Sentiment: Analyst targets are above the current share price, but the target dispersion and mixed ratings suggest uncertainty about JAN’s ability to convert revenue growth into earnings. The company recently reported revenue of $216.5 million, above estimates and up 45.4% year over year, but quarterly EPS of $0.05 missed consensus by $0.18.
• Negative Sentiment: The earnings shortfall remains an overhang. JAN’s fiscal 2026 EPS guidance of $0.95 to $0.98 is broadly in line with the approximately $0.97 analysts expect, leaving limited room for further disappointments or downward revisions.

About JAN

JanOne Inc is a technology and life sciences company focused on addressing the global opioid crisis. The company’s activities include developing and supporting pharmaceutical and other solutions intended to help reduce opioid-related deaths and dependency.

JanOne has also pursued blockchain and financial technology initiatives through its Alt 5 Sigma operations. These activities have included blockchain-based payment, digital asset and financial services solutions designed to help businesses manage transactions and related digital assets.

The company serves markets through its healthcare, technology and financial services initiatives, with an emphasis on solutions that can be applied internationally.